Skip Navigation


Annals of Oncology Advance Access originally published online on April 7, 2005
Annals of Oncology 2005 16(5):683-685; doi:10.1093/annonc/mdi167
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
16/5/683    most recent
mdi167v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tondini, C.
Right arrow Articles by Labianca, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tondini, C.
Right arrow Articles by Labianca, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Editorial

Tailoring a tailored treatment: the importance of fine-tuning on the patient

C. Tondini* and R. Labianca

Department of Medical Oncology, Ospedali Riuniti, Bergamo, Italy

(* Email: carlo.tondini@ospedaliriuniti.bergamo.it)

The first 150 words of the full text of this article appear below.

Until very recently, 5 years of oral tamoxifen has been the standard of care for adjuvant hormonal treatment of post-menopausal women with endocrine-responsive early breast cancer (EBC) [1Go, 2Go]. Now things are changing. In January of this year [3Go], the ASCO Technology Assessment Panel issued an updated recommendation on the use of aromatase inhibitors (AIs) in this setting. The Panel's conclusions state that ‘The Panel believes that optimal adjuvant hormonal therapy for a postmenopausal woman with receptor-positive breast cancer includes an aromatase inhibitor as initial therapy or after treatment with tamoxifen. Women with breast cancer and their physicians must weigh the risks and benefits of all therapeutic options.’

This recommendation has been issued on the basis of early data coming from randomised clinical trials comparing different strategies that include an AI in the treatment of these women. Research strategies have ranged from head-to-head comparison of an AI . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?